Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00

Taysha Gene Therapies (NASDAQ:TSHA) had its price target upped by Needham & Company LLC from $10.00 to $12.00 in a research note published on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also issued research reports about the stock. Chardan Capital restated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday. Raymond James Financial reissued a “strong-buy” rating and set a $13.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, January 6th. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a report on Thursday, December 4th. UBS Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Finally, Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.09.

Taysha Gene Therapies Trading Down 3.5%

Shares of Taysha Gene Therapies stock opened at $4.40 on Thursday. The business has a fifty day simple moving average of $4.63 and a 200-day simple moving average of $4.56. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The firm has a market cap of $1.21 billion, a price-to-earnings ratio of -12.94 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. Taysha Gene Therapies had a negative return on equity of 62.55% and a negative net margin of 1,144.97%.The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. On average, equities analysts forecast that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Sean P. Nolan sold 41,312 shares of the firm’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $4.61, for a total transaction of $190,448.32. Following the completion of the sale, the chief executive officer directly owned 2,908,257 shares of the company’s stock, valued at $13,407,064.77. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Sukumar Nagendran sold 26,918 shares of the firm’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total transaction of $124,091.98. Following the transaction, the insider directly owned 1,317,389 shares in the company, valued at approximately $6,073,163.29. The trade was a 2.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 598,623 shares of company stock worth $2,822,188. Corporate insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd raised its holdings in Taysha Gene Therapies by 698.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,577 shares of the company’s stock valued at $141,000 after buying an additional 22,373 shares in the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Taysha Gene Therapies during the 4th quarter valued at about $920,000. Invesco Ltd. increased its holdings in shares of Taysha Gene Therapies by 376.3% during the 4th quarter. Invesco Ltd. now owns 1,332,780 shares of the company’s stock valued at $7,330,000 after acquiring an additional 1,052,987 shares during the last quarter. Oracle Investment Management Inc. bought a new position in shares of Taysha Gene Therapies in the 4th quarter valued at approximately $1,458,000. Finally, Voloridge Investment Management LLC acquired a new stake in Taysha Gene Therapies in the 4th quarter worth approximately $301,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

More Taysha Gene Therapies News

Here are the key news stories impacting Taysha Gene Therapies this week:

• Positive Sentiment: Q4 2025 results topped expectations — reported EPS of ~$-0.087 vs. consensus ~$-0.096 and revenue of $5.49M well above estimates; management highlighted momentum on programs and financial results. Earnings Call Transcript (InsiderMonkey)
• Positive Sentiment: TSHA‑102 pivotal trial enrollment advancing and company says it’s on track to complete dosing in Q2 2026 with a 2026 BLA submission path — a clear clinical catalyst for future value. BLA Submission Path (MSN)
• Positive Sentiment: Analyst optimism picked up — Needham raised its price target to $12 (buy) and Chardan reaffirmed a $12 buy target, signaling sizable upside from current levels and likely contributing to increased attention. Analyst Coverage (Benzinga)
• Positive Sentiment: Company highlighted a strong cash position on the earnings call, which supports ongoing pivotal enrollment and development activity. Earnings Highlights (Yahoo Finance)
• Neutral Sentiment: Full earnings/management commentary and call transcripts are available from multiple outlets for investors who want the full details and Q&A. Transcript (Seeking Alpha)
• Negative Sentiment: Company remains unprofitable with a very negative net margin and negative return on equity; development risk and cash burn remain material risks until regulatory milestones or commercialization are achieved. Full Results & Corporate Update (GlobeNewswire)

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.